{
    "nct_id": "NCT05100472",
    "official_title": "Phase II Trial of Short Course Androgen Deprivation, Hypofractionated Pelvic Radiation and a Brachytherapy Boost for NCCN High-Risk Prostate Cancer With Low-Intermediate Risk Decipher Genomic Score",
    "inclusion_criteria": "* Pathologically-proven diagnosis of prostate adenocarcinoma\n* Clinical stage T3-4 or Gleason score 8-10 or PSA >20 ng/ml\n\n  °If radiographic T3-T4 is the only high-risk factor, it must be \"consistent with\" or >90% probability of having T3-T4 disease determined by the reading radiologist.\n* Decipher genomic score ≤0.6\n* Willing and able to provide written informed consent and Authorization for Use and Release of Health and Research Study Information (HIPAA authorization)\n* Age ≥18\n* KPS ≥70 or ECOG 0-2\n* Estimated life expectancy >5 years\n* Baseline prostate volume ≤90 cc\n* Baseline IPSS ≤20\n* No contraindications to ADT, brachytherapy, or pelvic external beam radiation therapy as determined by the treating radiation oncologist per standard practice\n* Patients who have already started ADT consisting of bicalutamide 50 mg PO daily with leuprolide or an equivalent GnRH analogue are eligible if given for ≤ 60 days prior to registration\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Regional lymph node or metastatic disease\n* Prior pelvic radiation\n* Prior prostate surgery (including TURP or cryosurgery)\n* Prior history of inflammatory bowel disease\n* Unable to undergo anesthesia or brachytherapy\n* Active second malignancy or past history of malignancies diagnosed within the last 2 years that requires active therapy and/or in remission, with the exception of resected non-melanoma skin cancers, non-muscle invasive bladder cancer, stage I head and neck cancer, or stage I colorectal cancer",
    "miscellaneous_criteria": ""
}